Psilocybin for Substance Use Disorders (SUD): adverse events

ClinicalTrials.gov adverse events: Nausea 24/50 (48%) in Psilocybin.

ClinicalTrials.gov adverse events: Nausea 10/48 (20.8%) in Psilocybin.

ClinicalTrials.gov adverse events: Nausea 10/48 (20.8%) in Psilocybin.

ClinicalTrials.gov adverse events: Nausea 10/48 (20.8%) in Psilocybin.

Consistent with our earlier report on the initial 12 patients from this trial, transient anxiety lasting for minutes (n = 15) and headaches lasting no more than 1-2 days (n = 8) were the most common side effects. Five reported transient nausea but there were no cases of vomiting.

The most common adverse events were transient anxiety (mostly mild) during drug onset (n=12), transient confusion or thought disorder (n=9), mild and transient nausea (n=4), and transient headache (n=4; table).

ClinicalTrials.gov adverse events: Anxiety 7/48 (14.6%) in Psilocybin.

ClinicalTrials.gov adverse events: Anxiety 7/48 (14.6%) in Psilocybin.

ClinicalTrials.gov adverse events: Insomnia 3/48 (6.3%) in Psilocybin.

ClinicalTrials.gov adverse events: Insomnia 3/48 (6.3%) in Psilocybin.

ClinicalTrials.gov adverse events: Insomnia 3/50 (6%) in Psilocybin.

ClinicalTrials.gov adverse events: Insomnia 3/48 (6.3%) in Psilocybin.

ClinicalTrials.gov adverse events: Vomiting 3/50 (6%) in Psilocybin.

of participants 2 (15.4) Vomiting 2 (15.4)Nausea 1 (7.7)Cardiac disorders, total no.

ClinicalTrials.gov adverse events: Vomiting 2/48 (4.2%) in Psilocybin.

ClinicalTrials.gov adverse events: Vomiting 2/48 (4.2%) in Psilocybin.

ClinicalTrials.gov adverse events: Fatigue 6/24 (25%) in Ketamine+Education.

ClinicalTrials.gov adverse events: Fatigue 5/50 (10%) in Psilocybin.

ClinicalTrials.gov adverse events: Fatigue 4/25 (16%) in Placebo+Education.

on site erythema 1 (7.7)Fatigue 1 (7.7)Investigations, total no. of participants 4 (30.8) Blood pressure increased 4 ( Nervous system disorders, total no. of participants 2 ( Paraesthesia 1 (7.7)Gastrointestinal disorders, total no. o